AHCO Quote, Financials, Valuation and Earnings

Axogen has a net margin of 3.41% compared to AdaptHealth's net margin of 0.91%. AdaptHealth's return on equity of 6% beat Axogen's return on equity of -10.21%.

AdaptHealth has a consensus price target of $13.00, signalling upside risk potential of 35.28%. On the other hand Axogen has an analysts' consensus of $25.00 which suggests that it could grow by 45.69%. Given that Axogen has higher upside potential than AdaptHealth, analysts believe Axogen is more attractive than AdaptHealth.

AdaptHealth has a beta of 1.302, which suggesting that the stock is 30.157% more volatile than S&P 500. In comparison Axogen has a beta of 1.024, suggesting its more volatile than the S&P 500 by 2.388%.

AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. Axogen pays out -- of its earnings as a dividend.

AdaptHealth quarterly revenues are $1.5B, which are larger than Axogen quarterly revenues of $49.4M. AdaptHealth's net income of $50.3M is higher than Axogen's net income of $450K. Notably, AdaptHealth's price-to-earnings ratio is 16.02x while Axogen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.40x versus 4.05x for Axogen. Usually stocks with elevated PS ratios are considered overvalued.

Elanco Animal Health has a net margin of 3.41% compared to AdaptHealth's net margin of -0.78%. AdaptHealth's return on equity of 6% beat Elanco Animal Health's return on equity of 5.48%.

AdaptHealth has a consensus price target of $13.00, signalling upside risk potential of 35.28%. On the other hand Elanco Animal Health has an analysts' consensus of $15.42 which suggests that it could grow by 49.53%. Given that Elanco Animal Health has higher upside potential than AdaptHealth, analysts believe Elanco Animal Health is more attractive than AdaptHealth.

AdaptHealth has a beta of 1.302, which suggesting that the stock is 30.157% more volatile than S&P 500. In comparison Elanco Animal Health has a beta of 1.439, suggesting its more volatile than the S&P 500 by 43.861%.

AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Elanco Animal Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. Elanco Animal Health pays out -- of its earnings as a dividend.

AdaptHealth quarterly revenues are $1.5B, which are larger than Elanco Animal Health quarterly revenues of $1B. AdaptHealth's net income of $50.3M is higher than Elanco Animal Health's net income of -$8M. Notably, AdaptHealth's price-to-earnings ratio is 16.02x while Elanco Animal Health's PE ratio is 15.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.40x versus 1.15x for Elanco Animal Health. Usually stocks with elevated PS ratios are considered overvalued.

Fulcrum Therapeutics has a net margin of 3.41% compared to AdaptHealth's net margin of 69.26%. AdaptHealth's return on equity of 6% beat Fulcrum Therapeutics's return on equity of -8.07%.

AdaptHealth has a consensus price target of $13.00, signalling upside risk potential of 35.28%. On the other hand Fulcrum Therapeutics has an analysts' consensus of $5.67 which suggests that it could grow by 95.4%. Given that Fulcrum Therapeutics has higher upside potential than AdaptHealth, analysts believe Fulcrum Therapeutics is more attractive than AdaptHealth.

AdaptHealth has a beta of 1.302, which suggesting that the stock is 30.157% more volatile than S&P 500. In comparison Fulcrum Therapeutics has a beta of 2.198, suggesting its more volatile than the S&P 500 by 119.83%.

AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fulcrum Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. Fulcrum Therapeutics pays out -- of its earnings as a dividend.

AdaptHealth quarterly revenues are $1.5B, which are larger than Fulcrum Therapeutics quarterly revenues of $80M. AdaptHealth's net income of $50.3M is higher than Fulcrum Therapeutics's net income of -$16.6M. Notably, AdaptHealth's price-to-earnings ratio is 16.02x while Fulcrum Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.40x versus -- for Fulcrum Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of 3.41% compared to AdaptHealth's net margin of -2.16%. AdaptHealth's return on equity of 6% beat Myomo's return on equity of -48.64%.

AdaptHealth has a consensus price target of $13.00, signalling upside risk potential of 35.28%. On the other hand Myomo has an analysts' consensus of $8.85 which suggests that it could grow by 74.56%. Given that Myomo has higher upside potential than AdaptHealth, analysts believe Myomo is more attractive than AdaptHealth.

AdaptHealth has a beta of 1.302, which suggesting that the stock is 30.157% more volatile than S&P 500. In comparison Myomo has a beta of 1.609, suggesting its more volatile than the S&P 500 by 60.902%.

AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

AdaptHealth quarterly revenues are $1.5B, which are larger than Myomo quarterly revenues of $12.1M. AdaptHealth's net income of $50.3M is higher than Myomo's net income of -$260.1K. Notably, AdaptHealth's price-to-earnings ratio is 16.02x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.40x versus 5.88x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.